SMC Approves Alimera’s Iluvien for NHS Scotland
Alimera Sciences yesterday announced that the Scottish Medicines Consortium (SMC) has approved Iluvien as a treatment for chronic diabetic macular oedema (DME) for restricted use within the NHS in the country. Use of Iluvien will be restricted to patients in whom the affected eye is pseudophakic, meaning that they have an artificial lens after cataract